Claritus Pharmaceuticals Inc. (CLAZF)

[TheShadow]

As previously disclosed in more detail in the Company’s press release dated September 11, 2019, proceeds of the Private Placement will be used to fund preparatory work for initiation of the Company’s Phase 3 clinical registration study for its lead product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). Proceeds will also be used to augment the Company’s working capital as it enters into discussions with potential corporate partners for its GVHD program.

https://kalytera.co/news/kalytera-announces-closing-of-final-tranche-of-private-placement-of-common-shares-and-common-share-purchase-warrants-and-amendments-to-secured-convertible-debenture-units/